{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-016548","form_type":"8-K","ticker":"ATYR","cik":"0001339970","company_name":"aTYR PHARMA INC","filed_at":"2022-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.313717+00:00","generated_at":"2026-06-26T02:30:46.020912+00:00","sec_items":["5.02","5.07","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"aTyr Pharma stockholders approve doubling authorized shares to 85M","bullets":["Stockholders approved increase in authorized common shares from 42.5M to 85,000,000.","Amendment to 2015 Stock Plan approved, increasing reserved shares by 2,000,000.","Amendment to 2015 ESPP approved, increasing reserved shares by 750,000 and per-employee limit to 2,500.","All three Class I director nominees elected (John Clarke, Paul Schimmel, Sara Zaknoen).","Ratification of Ernst & Young as auditor and advisory approval of executive compensation."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-016548","json":"https://secwatch.observer/filing/0001564590-22-016548.json","markdown":"https://secwatch.observer/filing/0001564590-22-016548.md","text":"https://secwatch.observer/filing/0001564590-22-016548.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339970/000156459022016548/0001564590-22-016548-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339970/000156459022016548/life-8k_20220426.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T02:30:46.020912+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}